11 – 19 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2015
-
Mark
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.
(
- Contribution to journal › Article
- 2014
-
Mark
Challenges for Children and Adolescents With Cancer in Europe: The SIOP-Europe Agenda
(
- Contribution to journal › Article
-
Mark
Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype
(
- Contribution to journal › Article
- 2012
-
Mark
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
(
- Contribution to journal › Article
-
Mark
BLUEPRINT to decode the epigenetic signature written in blood
(
- Contribution to journal › Letter
- 2011
-
Mark
Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2010
-
Mark
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood
(
- Contribution to journal › Article
-
Mark
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »